Transplant Diagnostics Market, By Product Type (Instrument, Reagents & Kits, and Software), By Technology (Molecular Assay, and Non-Molecular Assay), By Application (Tissue Typing, Infectious Disease Testing, Serum-Cross Matching, and Blood Profiling), By Organ Type (Kidney, Liver, Heart, Lungs, Pancreas, and Others), By End User (Hospitals & Transplant Centers, Research Laboratories & Academic Institutes, and Commercial Service Providers), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Dec 2023

Code : CMI1335

Pages :187

Formats :

Excel and PDF

Industry : Medical Devices

Market News

Recent Developments:

New product launches:

On March 22, 2023, Quest Diagnostics, the nation's leading provider of diagnostic information services, unveiled a comprehensive suite of advanced diagnostics and support services, Quest Advanced Specialized Transplant Services, which is designed to broaden access to laboratory tests for transplanting solid organ, human cells and tissue.
In March 2022, Immucor, Inc., a global leader in transfusion and transplantation diagnostics, announced two additions to its transplant diagnostics portfolio, demonstrating their ongoing commitment to new advancements in the field of histocompatibility. The company announced the global launch of MIA FORA NGS EXPRESS HLA Typing Software. This new software offering gives users of MIA FORA NGS MFlex HLA Typing assays a faster and easier NGS analysis experience.
In May 2022, Hologic, Inc., a medical technology company, announced the U.S. Food and Drug Administration (FDA) had approved its Aptima CMV Quant assay to quantify the viral load of cytomegalovirus (CMV) in patients who have had solid organ or stem cell transplants. The test is the first to be introduced in the U.S. by Hologic for post-transplant pathogen detection and monitoring on Hologic’s fully automated Panther system, and joins the existing portfolio of diagnostic and viral load testing for HIV-1, Hepatitis C and Hepatitis B.

Collaboration and Acquisitions:

On November 21, 2023, GenDx, a Eurobio Scientific Company, announced it had entered into a collaboration with OSE Immunotherapeutics, a biotech company dedicated to developing first-in-class assets in immuno-oncology, to develop and validate a companion diagnostic (CDx) test for high resolution typing of HLA-A*02 based on their IVDR registered NGSgo kit and NGSengine software.
In November 2022, Werfen, a worldwide leader in specialized diagnostics in the specialties of hemostasis, acute care diagnostics, transfusion, autoimmunity and transplant, announced it had agreed to acquire Immucor, Inc., from TPG. Immucor is a privately held corporation with a strong global presence in transfusion and transplant in vitro diagnostics. This acquisition will allow Werfen to expand its portfolio of Specialized Diagnostics solutions for hospitals and clinical laboratories.
In October 2022, Immucor, Inc., and Pirche AG, the global leader in artificial intelligence (AI)-powered molecular matching and prediction analysis, announced a multi-year partnership to expand Immucor’s transplant diagnostic software, representing a continued contribution of novel approaches to innovate in the field of histocompatibility. Immucor will also make an investment in Pirche as part of this partnership.